Ligandal
Biotechnology, 650 5th St, San Francisco, California, 94107, United States, 11-50 Employees
Phone Number: 65********
Who is LIGANDAL
Ligandal is a genetic medicine company that uses nanotechnology to develop targeted and personalised therapies. As a regenerative medicine biotechnology company, Ligandal develops ultra-r...
Read More
-
Headquarters: 650 5th St, San Francisco, California, 94107, United States
-
Date Founded: 2013
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
Ligandal Org Chart and Mapping
Email
Phone
Similar Companies to Ligandal
Beam Therapeutics
-
501-1000
-
$ 50 Million to 100 Million
Sama Therapeutics
-
11-50
-
$ 500 Million to 1 Billion
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Ligandal
Answer: Ligandal's headquarters are located at 650 5th St, San Francisco, California, 94107, United States
Answer: Ligandal's phone number is 65********
Answer: Ligandal's official website is https://ligandal.com
Answer: Ligandal's revenue is $1 Million to $5 Million
Answer: Ligandal's SIC: 8731
Answer: Ligandal has 11-50 employees
Answer: Ligandal is in Biotechnology
Answer: Ligandal top competitors include: Beam Therapeutics , Sama Therapeutics
Answer: Ligandal contact info: Phone number: 65******** Website: https://ligandal.com
Answer: Ligandal is a genetic medicine company that uses nanotechnology to develop targeted and personalised therapies. As a regenerative medicine biotechnology company, Ligandal develops ultra-rapid therapeutics and vaccines for outbreaks and pandemics, in addition to its work in immuno-oncology and rare genetic diseases. Our current focus is on delivering a peptide-based cure to the COVID-19 pandemic (SARS-CoV-2 coronavirus), as part of a broader mission of enabling personalized medicine on a global scale through the power of nanomedicine and gene therapies. Given that increasingly complex disease states require precise and custom-tailored medicine, much of our technology development has focused on combining gene therapy with targeting peptides to enable completely new paradigms in evolutionary medicine. Currently, we are utilizing a peptide nanoscaffold based approach for treating COVID-19 without a gene therapy component, with the goal of creating a combined antidote-vaccine. My expertise lies in targeted gene delivery, nano- and biomaterials, computational modeling of peptides, binding simulations, immunoengineering, as well as CRISPR and TALEN based gene editing. At Ligandal, we have demonstrated peptide-based delivery of CRISPR, RNA, DNA, siRNA, and a range of genes or proteins to virtually any cell type.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month